Aqemia, a Paris, France-based techbio company that teaches atomic scale physics to a generative AI to develop new medicines, raised $38M in funding.
The round, which brought the total amount to $100M, was led by Cathay Innovation, followed by historical investors Wendel, Bpifrance Large Venture, Eurazeo, and Elaia.
The company intends to use the funds to support its development goals, including preparations for clinical trials.
Led by CEO Maximilien Levesque, Aqemia is a techbio company building drug discovery pipelines for critical diseases. It has already achieved several drug discovery successes within its internal pipeline and through collaborations with pharmaceutical companies, with its programs currently undergoing in vivo optimization.
In addition to reaching the $100M funding milestone, the company announced the opening of its London office, scheduled for January 2025 in the King’s Cross area. This expansion strengthens its presence in the UK’s dynamic tech and biotech sectors. The new location will provide access to the UK’s rich talent pool, especially in life sciences and techbio, as the company continues its global recruitment efforts across all levels.
FinSMEs
10/12/2024